We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-10.66%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$551M
AUM Growth
–
Cap. Flow
+$550M
Cap. Flow %
99.74%
Top 10 Hldgs %
31.05%
Holding
130
New
130
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$21.7M
2
GILD icon
Gilead Sciences
GILD
+$21M
3
MDT icon
Medtronic
MDT
+$20.8M
4
BIIB icon
Biogen
BIIB
+$20.2M
5
AMGN icon
Amgen
AMGN
+$15.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 93%
2 Financials 1.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$167B
$21.4M 3.89%
+233,300
New +$21M
CELG
2
DELISTED
Celgene Corp
CELG
$21.1M 3.82%
+210,550
New +$21.7M
MDT icon
3
Medtronic
MDT
$106B
$20.7M 3.76%
+276,500
New +$20.8M
BIIB icon
4
Biogen
BIIB
$30.4B
$19.9M 3.62%
+76,540
New +$20.2M
ABT icon
5
Abbott
ABT
$175B
$16M 2.9%
+381,500
New +$15.1M
AMGN icon
6
Amgen
AMGN
$198B
$15.4M 2.8%
+103,000
New +$15.3M
BDX icon
7
Becton Dickinson
BDX
$43.6B
$15.2M 2.76%
+102,731
New +$14.6M
ILMN icon
8
Illumina
ILMN
$28.2B
$14.9M 2.7%
+94,191
New +$14.4M
SYK icon
9
Stryker
SYK
$123B
$13.4M 2.43%
+125,000
New +$12.3M
CAH icon
10
Cardinal Health
CAH
$53.5B
$13.1M 2.37%
+159,630
New +$13M
UNH icon
11
UnitedHealth
UNH
$387B
$12M 2.18%
+93,000
New +$11M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$70.9B
$11.7M 2.12%
+32,400
New +$13.4M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$37.3B
$10.4M 1.9%
+195,290
New +$11.5M
VTRS icon
14
Viatris
VTRS
$20.1B
$10.2M 1.85%
+220,000
New +$10.6M
BSX icon
15
Boston Scientific
BSX
$65.4B
$9.4M 1.71%
+500,000
New +$8.78M
ZBH icon
16
Zimmer Biomet
ZBH
$17.6B
$9.19M 1.67%
+88,786
New +$8.59M
CVS icon
17
CVS Health
CVS
$137B
$8.94M 1.62%
+86,200
New +$8.38M
LGND icon
18
Ligand Pharmaceuticals
LGND
$6.08B
$8.76M 1.59%
+131,173
New +$7.97M
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$15.5B
$8.16M 1.48%
+62,500
New +$7.78M
CYTO
20
DELISTED
Altamira Therapeutics Ltd
CYTO
$7.9M 1.43%
+27
New +$9.61M
ISRG icon
21
Intuitive Surgical
ISRG
$122B
$7.81M 1.42%
+117,000
New +$7.25M
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$6.88M 1.25%
+49,400
New +$7.25M
MCK icon
23
McKesson
MCK
$98.5B
$6.76M 1.23%
+43,000
New +$6.95M
SUPN icon
24
Supernus Pharmaceuticals
SUPN
$2.79B
$6.72M 1.22%
+441,000
New +$5.75M
STJ
25
DELISTED
St Jude Medical
STJ
$6.71M 1.22%
+122,000
New +$6.65M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2016 Portfolio in Review

Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.

Its largest position is Celgene Corp: 210,550 shares worth $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Financials.

  • Bellevue Group's largest Q1 2016 buy was Celgene Corp: 210,550 shares worth $21.1M.
  • Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
  • Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.

Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.